Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

MATRIx Understanding Nanoparticle Transport Mechanisms in the Melanoma Microenvironment via a Tumor-on-a-Chip Approach

Coordinator
Politecnico Di Milano, Italy
Runs
16 October 2025 to 15 January 2028
Status
Running
EU funding
€236k
Total cost
—
Partners
3 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101205238

What the project is doing

In the project's own words, from its summary on CORDIS.

The MATRIx aims to develop a 3D melanoma tumor model on a chip (ToC) using patient-derived xenograft technology, which mimics the natural tumor microenvironment (TME) to enhance nanoparticle (NP) delivery to the tumor site and enable personalized treatment. In Western countries, melanoma is considered one of the most widespread cancers. Due to its aggressive nature and resistance to drugs, melanoma is the subject of extensive research aimed at creating more effective medications.

The clinical translation of nanomedicine for cancer therapy has been hindered by a lack of knowledge regarding the TME, mechanisms of NP uptake and transfer, technical limitations for model implementation, and individual variations in phenotype. ToC modeling is an indispensable tool in cancer research providing a 3D dynamic environment with regulated fluid flow and shear stress, co-culturing, vascularization, easy operation and readout method, and time and cost saving in contrast to other cancer models. in addition, ToC provides high-throughput screening of nanomedicines, susceptibility, and resistance of cancer cells against drugs, allowing personalized therapy for patients with low cost and high reproducibility.

Development of NPs based on patient’s melanoma TME response to active targeting NPs is the focus of MATRIx which will be implemented for the first time. My project's key deliverables will consist of identifying key players of TME around NP extravasation and enhancing NP retention at the tumor site. This initiative will aid in the development of more effective personalized cancer treatment strategies and will be of considerable interest to both academic and industrial sectors.

MATRIx also fills my knowledge gaps. Following MATRIX conclusion, I will establish myself as a leader in the field of NP development, alongside tumor modeling on chip technology. I will receive advanced training skills to equip myself for conducting independent research and securing a permanent academic role.

Topics

Who is involved

OrganisationCityCountryRole
Politecnico Di MilanoMilanoItalyCoordinator
Biomimx SRLMilanoItalyAssociatedpartner
Istituto Europeo Di Oncologia SRLMilanoItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI